In The News

Protective threshold of a potent neutralizing Zika virus monoclonal antibody in rhesus macaques

Monoclonal antibodies against the spike protein alter the endogenous humoral response to SARS-CoV-2 vaccination and infection

Mpox infection of stromal cells and macrophages of macaque with endometriosis

Mucosal adenovirus vaccine boosting elicits IgA and durably prevents XBB.1.16 infection in nonhuman primates

Comparison of the immunogenicity of mRNA-encoded and protein HIV-1 Env-ferritin nanoparticle designs

Variant-proof high affinity ACE2 antagonist limits SARS-CoV-2 replication in upper and lower airways

NK cells modulate in vivo control of SARS-CoV-2 replication and suppression of lung damage

Arenavirus-Based Vectors Generate Robust SIV Immunity in Non-Human Primates

This press release details the collaboration between BIOQUAL, Inc. and Virginia Tech who established the cynomolgus macaque as one of the first non-human primate models of Mayaro virus infection.

A non-human primate model for human norovirus infection

BIOQUAL, Inc., in collaboration with Dan Barouch and his team at BIDMC, recently published an article in Science Translational Medicine. For this proof-of-concept study, rhesus macaques were vaccinated with the licensed ACAM2000 or JYNNEOS vaccines or with an Adenovirus-based vector that expressed 2 or 4 vaccinia virus antigens. Differences between the vaccines allowed an investigation of immune correlates of protection against Mpox. Details about the study can be found in the link below.

Comparison of the immunogenicity and protective efficacy of ACAM2000, MVA, and vectored subunit vaccines for Mpox in rhesus macaques | Science Translational Medicine

BIOQUAL, Inc. would like to thank all the staff that made this possible:
The caretakers, animal techs, behaviorists, laboratory staff and many more. Thank you all for hard work and commitment to our mission of improving global health.